|
Michael McGuinness joined Manhattan Pharmaceuticals in July 2006. He is a 30-year veteran of the financial and life science industries, including 17 years experience as chief financial officer. Mr. McGuinness joined Manhattan Pharmaceuticals from Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), a product-based drug delivery company, where he served as chief financial officer from 2001 to 2006. During his tenure there Mr. McGuinness played key roles in strategic planning, securing several key partnership deals, and overseeing financing transactions that raised more than $60 million in capital. He also led Vyteris' reverse merger transaction which resulted in the company becoming a publicly traded entity. From 1998 to 2001 Mr. McGuinness served as the Chief Financial Officer and a member of the board of directors of EpiGenesis Pharmaceuticals, Inc., a privately-held biotechnology company, where he was a member of the negotiating team on two out-licensing agreements valued at $135 million. He also served as Chief Financial Officer of BlueStone Capital Partners, an investment bank and broker/dealer. Mr. McGuinness received a BBA in public accounting from Hofstra University and is a member of the American Institute of Certified Public Accountants.
| 